乙型和丙型肝炎病毒与生物制剂

Hepatitis B and C Viruses and Biologics.

作者信息

Grewal P, Sanghera R

机构信息

Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, AB, Canada.

出版信息

Skin Therapy Lett. 2017 Jul;22(4):7-9.

PMID:28732153

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are common, worldwide viral illnesses that potentially impact the clinician's ability to manage patients with immunosuppressive medications such as biological therapy. In light of recent literature reviews, patients with HBV and HCV should be referred to a hepatologist or infectious disease expert prior to initiation of biological therapy.

摘要

乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）是全球常见的病毒性疾病，可能会影响临床医生使用生物疗法等免疫抑制药物治疗患者的能力。根据最近的文献综述，患有HBV和HCV的患者在开始生物治疗之前应转诊至肝病专家或传染病专家处。